The one-time non-surgical procedure involves passing a special catheter through a bronchoscope into the lungs. The catheter delivers a type of electrical energy called radiofrequency (RF) energy to the nerves located on the outside of the airways. Once the energy has been delivered, the catheter and bronchoscope are removed. The procedure takes about one hour.

Video Script

Do you or someone you know suffer from Chronic Obstructive Pulmonary Disease, commonly known as COPD? A new therapy called Targeted Lung Denervation is being investigated in the AIRFLOW-2 Clinical Trial.

For most people with normal lung function, breathing is easy – the airways are wide openwith minimal inflammation or mucus.When you suffer from COPD you may experience shortness of breath, wheezing, chest tightness, airway inflammation, and a cough that produces mucus.

Targeted Lung Denervation or TLD is a non-surgical procedure that interrupts nerve signals and may reduce COPD symptoms, helping you to breathe easier. A standard bronchoscope is passed through the patient’s mouth and into the lungs and a special catheter is passed through thebronchoscope to provide the treatment.

Once the catheter is in place the balloon is inflated. Notice the silver electrode on the inflated balloon. When activated, the electrode delivers a type of electrical energy called radiofrequency (RF) energy, which penetrates to interrupt the nerves located just outside of the airways. Once the energy has been delivered in one position, the balloon is deflated and rotated to the next position. This is continued for four total treatment positions. Upon completion, the catheter is removed and the animation shows that the nerves distal to the treatment site have been interrupted decreasing nerve signals throughout the lung on that side. The catheter is then placed in the lung on the opposite side and the treatment is continued in four positions. The entire treatment is now complete and the catheter and bronchoscope are removed.

Notice how the nerves from the treatment site and below have been interrupted as shown by the color change from yellow to dark green.  The magnification demonstrates how the treatment effect extends all the way from the actual treatment site out to the smallest airways.

Following TLD, we expect to see a relaxation of the airway, a decrease in mucus production and a decrease in airway wall inflammation.With these improvements the air can now more readily pass into and out of the lungs. Breathing becomes much less labored and lung function may improve.

If you would like more information on this investigational COPD therapy, please contact us at research@nuvaira.com